Patents by Inventor Okjae Lim

Okjae Lim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220251176
    Abstract: A fusion protein including a fragment of an anti-mesothelin antibody, an anti-CD3 antibody or an anti-EGFR antibody; a bispecific antibody that is specific to mesothelin and CD3; a trispecific antibody that is specific to mesothelin, CD3 and EGFR are provided. The fusion protein is effective in treating cancer. The bispecific or trispecific antibody can be prepared in a high yield and with high purity, and has excellent tumor killing and growth inhibitory effects, and thus can be effectively used in cancer treatment.
    Type: Application
    Filed: December 16, 2019
    Publication date: August 11, 2022
    Applicants: GREEN CROSS CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Yangmi LIM, Shinai LEE, Jonghwa WON, Yong-Yea PARK, Aerin YOON, Sua LEE, Okjae LIM, Sojung LIM, Munkyung KIM
  • Patent number: 9834753
    Abstract: The present invention relates to a method for producing natural killer cells (hereinafter, referred to as “NK cells”), NK cells produced thereby, and a composition for treating cancers and infectious diseases containing the same. The present invention provides a method for producing NK cells, which maintain high cytotoxicity and cell viability to exhibit high therapeutic effects against cancers and infectious diseases and can be cultured ex vivo at high efficiency and high concentration. In addition, a culture method which maintains cell concentration at a constant level is used for the production of NK cells, and thus the overgrowth of the cells can be prevented so that the cells can be maintained at an optimal state. Particularly, even when the cells are thawed after freezing, the function of the cells is not impaired, and the NK cells can maintain high cell viability and cytotoxicity.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: December 5, 2017
    Assignees: GREEN CROSS LABCELL, MOGAM BIOTECHNOLOGY INSTITUTE
    Inventors: Bokyung Min, Hana Choi, Okjae Lim, Jung Hyun Her, Sangmi Kang, Eun-Kyoung Lee, Hyejin Chung, Yu Kyeong Hwang
  • Publication number: 20150118207
    Abstract: The present invention relates to a method for producing natural killer cells (hereinafter, referred to as “NK cells”), NK cells produced thereby, and a composition for treating cancers and infectious diseases containing the same. The present invention provides a method for producing NK cells, which maintain high cytotoxicity and cell viability to exhibit high therapeutic effects against cancers and infectious diseases and can be cultured ex vivo at high efficiency and high concentration. In addition, a culture method which maintains cell concentration at a constant level is used for the production of NK cells, and thus the overgrowth of the cells can be prevented so that the cells can be maintained at an optimal state. Particularly, even when the cells are thawed after freezing, the function of the cells is not impaired, and the NK cells can maintain high cell viability and cytotoxicity.
    Type: Application
    Filed: December 18, 2012
    Publication date: April 30, 2015
    Applicants: Mogam Biotechnology Institute, Green Cross Labcell
    Inventors: Bokyung Min, Hana Choi, Okjae Lim, Jung Hyun Her, Sangmi Kang, Eun-Kyoung Lee, Hyejin Chung, Yu Kyeong Hwang
  • Patent number: 7785875
    Abstract: There are provided a polynucleotide encoding HCV epitopes, an immunogenic composition including same, and a method of inducing an HCV-specific immune response using same.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: August 31, 2010
    Assignee: Mogam Biotechnology Research Institute
    Inventors: Yu Kyeong Hwang, Okjae Lim, Hyejin Chung
  • Publication number: 20090162317
    Abstract: There are provided a polynucleotide encoding HCV epitopes, an immunogenic composition including same, and a method of inducing an HCV-specific immune response using same.
    Type: Application
    Filed: November 3, 2008
    Publication date: June 25, 2009
    Applicant: Mogam Biotechnology Research Institute
    Inventors: Yu Kyeong Hwang, Okjae Lim, Hyejin Chung
  • Publication number: 20080112977
    Abstract: The present invention relates to a supertype epitope which effectively induce a cell-mediated immune response and its use, specifically, a supertype epitope which effectively induce the cytotoxic T lymphocytes specific to HCV and come from conservative region of a HCV polyprotein, an expression vector comprising the oligonucleotide coding the said supertype epitope, a vaccine composition comprising the said supertype epitope or the said expression vector and its use for treatment of hepatitis C.
    Type: Application
    Filed: July 4, 2005
    Publication date: May 15, 2008
    Applicant: MOGAM BIOTECHNOLOGY RESEARCH
    Inventors: Yu Kyeong Hwang, Nam Kyung Kim, Jung Min Park, Okjae Lim, Mahnhoon Park